eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated for Kidney Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Kidney Cancer. These NCCN Guidelines^® are currently available as Version 4.2023.

Link directly to the Updates section of the NCCN Guidelines: Kidney Cancer

KID-C (1 of 2)

• Principles of Systemic Therapy for Relapse or Stage IV Disease
  • Subsequent Therapy for Clear Cell Histology
    • Sorafenib was removed as a treatment option.
    • Preference stratification was significantly revised.
    • IO Therapy Naïve
      • Other Recommended Regimens
        • Nivolumab was changed to a category 2A recommendation.
        • Cabozantinib was changed to a category 2A recommendation.
      • Useful in Certain Circumstances
        • Axitinib was changed to a category 2A recommendation.
        • Tivozanib was changed to a category 2A recommendation.
    • Prior IO Therapy
      • Other Recommended Regimens
        • Axitinib was changed to a category 2A recommendation.
        • Cabozantinib was changed to a category 2A recommendation.
        • Tivozanib was changed to a category 2A recommendation

MS-1

• The Discussion was updated to reflect the changes in the algorithm.

Previous updates to the NCCN Guidelines for Kidney Cancer can be found in the UPDATES section of the current version.

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Kidney Cancer to reflect the currently published NCCN Guidelines for Kidney Cancer v4.2023.

•  The following template has been archived:
  • KDN8: SORAfenib
• Changes to the Indication section have been made to the following template:
  • KDN24: Nivolumab
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Nivolumab

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.